BioNTech raises Covid vaccine output goal to 2.5 bn doses
The company said the boost would allow it to "address increased demand" as countries around the world race to contain new, more contagious virus variants.
The plant will eventually produce up to one billion Covid jabs a year, once fully operational.
The vaccine is also being produced at a Pfizer plant in Belgium and at three sites in the United States.
BioNTech said improved efficiency and new cooperation agreements with outside partners had also helped lift its vaccine target, as had the regulatory nod allowing vaccinators to extract six instead of just five doses from a single BioNTech/Pfizer vial.
The BioNTech/Pfizer shot is based on novel mRNA technology and was the first Covid-19 vaccine to be approved in the West late last year.
Recent studies have shown that the jab is not only highly effective in protecting against Covid, it also provides protection against transmission of the virus.
"We will continue to focus on innovating in the COVID-19 field by advancing new formulations and addressing vaccine variants," he added.
The company's vaccine has also been buoyed by a green light from the European Medicines Agency last week allowing BioNTech/Pfizer vials to be kept at normal freezer temperatures for short periods, simplifying the jab's complex cold chain logistics.
In Tuesday's statement, BioNTech announced a net profit of 15.2 million euros for 2020, compared with a 179-million-euro loss in 2019.